MedTrace Logo

Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)

NCT00516737 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2024-04-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the effectiveness of rizatriptan benzoate in the early treatment of an acute migraine attack.

Conditions

Interventions

DRUG

Comparator: rizatriptan benzoate

Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack

DRUG

Comparator: Placebo

Matching placebo; one dose, treatment of a single migraine attack

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-03
Primary Completion
2008-04-08
Completion
2008-04-08

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00516737 on ClinicalTrials.gov